title: Computational analysis of drug transport in tumor microenvironment as a critical compartment for nanotherapeutic pharmacokinetics.
abstract: Over the last decade, nanotherapeutics gained increasingly important role in drug delivery because of their frequently beneficial pharmacokinetics (PK) and lower toxicity when compared to classical systemic drug delivery. In view of therapeutic payload delivery, convective transport is crucial for systemic distribution via circulatory system, but the target domain is tissue outside vessels where transport is governed by diffusion. Here, we have computationally investigated the understudied interplay of physical transports to characterize PK of payload of nanotherapeutics. The analysis of human vasculature tree showed that convective transport is still 5 times more efficient than diffusion suggesting that circulating and payload releasing drug vectors can contribute mostly to systemic delivery. By comparing payload delivery using systemic circulation and drug vectors to microenvironment, internalized vectors were the most efficient and showed Area under the Curve almost 100 higher than in systemic delivery. The newly introduced zone of influence parameter indicated that vectors, especially internalized, lead to the largest tissue fraction covered with therapeutically significant payload concentration. The internalization to microenvironment minimizes effects of plasma domain on payload extravasation from nanotherapeutics. The computed results showed that classical PK, which mostly relies on concentration profiles in plasma, sometimes might be inadequate or not sufficient in explaining therapeutic efficacy of nanotherapeutics. These results provide a deeper look into PK of drug vectors and can help in the design of better drug delivery strategies.
authors.affiliation: a The Department of Nanomedicine , Houston Methodist Research Institute , Houston , USA.
authors.forename: Arturas
authors.initials: A
authors.lastname: Ziemys
authors.affiliation: b Cure Technologies LLC , Grand Rapids , USA.
authors.forename: Steve
authors.initials: S
authors.lastname: Klemm
authors.affiliation: c Belgrade Metropolitan University , Kragujevac , Serbia , and.
authors.forename: Miljan
authors.initials: M
authors.lastname: Milosevic
authors.affiliation: a The Department of Nanomedicine , Houston Methodist Research Institute , Houston , USA.
authors.forename: Kenji
authors.initials: K
authors.lastname: Yokoi
authors.affiliation: a The Department of Nanomedicine , Houston Methodist Research Institute , Houston , USA.
authors.forename: Mauro
authors.initials: M
authors.lastname: Ferrari
authors.affiliation: a The Department of Nanomedicine , Houston Methodist Research Institute , Houston , USA.|c Belgrade Metropolitan University , Kragujevac , Serbia , and.|d Serbian Academy of Sciences and Arts , Belgrad , Serbia.
authors.forename: Milos
authors.initials: M
authors.lastname: Kojic
mesh_terms: D001692:Biological Transport; D004058:Diffusion; D016503:Drug Delivery Systems / Q000379:methods*; D065546:Drug Liberation; D006801:Humans; D053758:Nanoparticles / Q000737:chemistry*; D010599:Pharmacokinetics; D059016:Tumor Microenvironment / Q000187:drug effects*
keywords: Capillaries; diffusion; local concentration; pharmacokinetics; zone of influence
references.citation: Cancer Res. 2014 Aug 15;74(16):4239-46
references.pmid: 24853545
references.citation: ACS Nano. 2013 Sep 24;7(9):7442-7
references.pmid: 24490875
references.citation: Trends Biotechnol. 2010 Apr;28(4):181-8
references.pmid: 20079548
references.citation: Clin Pharmacol Ther. 2004 Nov;76(5):508; author reply 508-9
references.pmid: 15536466
references.citation: Comput Methods Appl Mech Eng. 2014 Feb 1;269:123-138
references.pmid: 24578582
references.citation: J Pharm Sci. 2014 Jul;103(7):2147-2156
references.pmid: 24801583
references.citation: Adv Enzyme Regul. 2001;41:189-207
references.pmid: 11384745
references.citation: Antimicrob Agents Chemother. 2004 May;48(5):1441-53
references.pmid: 15105091
references.citation: Cancer. 1984 Sep 15;54(6 Suppl):1175-8
references.pmid: 6467148
references.citation: J Control Release. 2000 Mar 1;65(1-2):271-84
references.pmid: 10699287
references.citation: Cancer Res. 1989 Dec 1;49(23):6449-65
references.pmid: 2684393
references.citation: Eur J Pharm Biopharm. 2007 Aug;67(1):39-47
references.pmid: 17329085
references.citation: Circ Res. 1973 Aug;33(2):190-7
references.pmid: 4727370
references.citation: J Serbian Soc Comput Mech. 2017;11(2):108-119
references.pmid: 29782608
references.citation: Nat Rev Immunol. 2010 Jun;10(6):453-60
references.pmid: 20467425
references.citation: Cancer Res. 1984 Jan;44(1):238-44
references.pmid: 6197161
references.citation: Nat Rev Drug Discov. 2008 Sep;7(9):771-82
references.pmid: 18758474
references.citation: J Pharm Sci. 2014 Mar;103(3):777-84
references.pmid: 24481705
references.citation: Lancet. 1994 May 14;343(8907):1184-7
references.pmid: 7909867
references.citation: J Clin Oncol. 2001 Jul 15;19(14):3312-22
references.pmid: 11454878
references.citation: Ann Oncol. 2004 Mar;15(3):440-9
references.pmid: 14998846
references.citation: Nat Rev Clin Oncol. 2010 Nov;7(11):653-64
references.pmid: 20838415